Xeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter

Benzinga
01-10

Other Fourth Quarter 2024 Updates

  • Recorlev achieved record number of new starts and referrals.
  • Gvoke ended the year with approximately 35% market share.
  • Keveyis maintained a similar number of patients on therapy as Q3 2024.
  • Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter.
  • Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect formulation technology. The termination will not have a material impact on Xeris' outlook.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

no data

沒有相關數據

如果下載按鈕點擊無跳轉,請點擊右上角菜單選擇 “在瀏覽器打開”